Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TARS logo TARS
Upturn stock rating
TARS logo

Tarsus Pharmaceuticals Inc (TARS)

Upturn stock rating
$74.95
Last Close (24-hour delay)
Today's Top Performer Top performer
Profit since last BUY56.64%
upturn advisory
Strong Buy
BUY since 48 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/15/2025: TARS (4-star) is a STRONG-BUY. BUY since 48 days. Simulated Profits (56.64%). Updated daily EoD!

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $78.38

1 Year Target Price $78.38

Analysts Price Target For last 52 week
$78.38 Target price
52w Low $35.84
Current$74.95
52w High $76.81

Analysis of Past Performance

Type Stock
Historic Profit 295.29%
Avg. Invested days 49
Today’s Advisory Strong Buy
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulation Last Close 10/15/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.16B USD
Price to earnings Ratio -
1Y Target Price 78.38
Price to earnings Ratio -
1Y Target Price 78.38
Volume (30-day avg) 8
Beta 0.81
52 Weeks Range 35.84 - 76.81
Updated Date 10/17/2025
52 Weeks Range 35.84 - 76.81
Updated Date 10/17/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.29

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -31.13%
Operating Margin (TTM) -21.61%

Management Effectiveness

Return on Assets (TTM) -14.06%
Return on Equity (TTM) -31.46%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2172226009
Price to Sales(TTM) 10.71
Enterprise Value 2172226009
Price to Sales(TTM) 10.71
Enterprise Value to Revenue 7.35
Enterprise Value to EBITDA -3.23
Shares Outstanding 42214106
Shares Floating 30387402
Shares Outstanding 42214106
Shares Floating 30387402
Percent Insiders 3.18
Percent Institutions 114.44

ai summary icon Upturn AI SWOT

Tarsus Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Tarsus Pharmaceuticals, Inc. was founded in 2016 and is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing novel therapeutics to address unmet needs. Their initial focus has been on eye care. Tarsus Pharmaceuticals is located in Irvine, California.

business area logo Core Business Areas

  • Pharmaceutical Development: Focuses on the research, development, and commercialization of new pharmaceutical products, particularly in eye care. Specializes in the treatment of Demodex blepharitis. Developing treatments in other areas like Meibomian gland dysfunction (MGD).

leadership logo Leadership and Structure

Dr. Bobak Azamian is the Chairman and CEO. The company has a management team with experience in pharmaceutical development and commercialization. The company structure is typical of a biotech firm, including research and development, clinical operations, commercial strategy, and financial management.

Top Products and Market Share

overview logo Key Offerings

  • XDEMVY (lotilaner ophthalmic solution) 0.25%: XDEMVY is FDA-approved for the treatment of Demodex blepharitis. Tarsus has launched XDEMVY into the market and is currently working on expanding its reach. Tarsus estimates that roughly 25 million people in the US have Demodex blepharitis. Tarsus expects the Demodex blepharitis market to be approximately $1 billion. Key competitors would be off-label treatments and compounded products, and Bausch & Lomb (BLCO) and other major ophthalmic players may introduce their own prescription treatments in the future.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly in eye care, is competitive and growing. There is significant demand for treatments for conditions like Demodex blepharitis. Development and regulatory processes are complex and time-consuming.

Positioning

Tarsus Pharmaceuticals is positioned as an innovative company focused on addressing underserved needs in eye care. They are the first to have an FDA-approved product for Demodex blepharitis.

Total Addressable Market (TAM)

The market for Demodex blepharitis treatment is estimated to be approximately $1 billion. Tarsus, with the approval of XDEMVY, is well-positioned to capture a significant portion of this market, particularly as the first FDA-approved therapy.

Upturn SWOT Analysis

Strengths

  • First FDA-approved treatment for Demodex blepharitis
  • Strong intellectual property protection
  • Experienced management team focused on eye care
  • Strong clinical trial results for XDEMVY

Weaknesses

  • Reliance on a single product (XDEMVY)
  • Limited commercial history as a relatively new company
  • Potential for competition from larger pharmaceutical companies
  • Manufacturing and supply chain dependencies

Opportunities

  • Expansion of XDEMVY into additional markets
  • Development of new therapies for other eye conditions
  • Partnerships with larger pharmaceutical companies
  • Increased awareness of Demodex blepharitis

Threats

  • Competition from generic or biosimilar products
  • Unfavorable regulatory changes
  • Failure to gain market acceptance for XDEMVY
  • Product liability claims

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

Tarsus Pharmaceuticals is the first to market with an FDA-approved treatment for Demodex blepharitis, giving it a competitive advantage. However, larger pharmaceutical companies may enter the market with competing products in the future. Tarsus Pharmaceuticals competes with Allergan (ABBV) and Bausch & Lomb (BLCO) in the eye care market.

Growth Trajectory and Initiatives

Historical Growth: Tarsus Pharmaceuticals is a young company with limited historical financial data available. Most of their growth trajectory is projected.

Future Projections: Analysts project significant revenue growth for Tarsus based on the launch of XDEMVY and potential expansion into other markets.

Recent Initiatives: Successful FDA approval and commercial launch of XDEMVY. Continued clinical development of additional eye care products.

Summary

Tarsus Pharmaceuticals is a promising biopharmaceutical company that is looking to continue innovating in the treatment of eye care conditions. With the FDA approval of XDEMVY, the company is positioned for significant growth. However, its reliance on a single product makes it vulnerable to competition and regulatory changes. Tarsus Pharmaceuticals needs to diversify its product pipeline and ensure successful commercialization of XDEMVY to sustain its growth trajectory.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Tarsus Pharmaceuticals Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on your own research and due diligence.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tarsus Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Irvine, CA, United States
IPO Launch date 2020-10-16
Co-Founder, President, CEO & Chairman Dr. Bobak R. Azamian M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 323
Full time employees 323

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.